Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic TKI Post-HSCT in Ph+ ALL with MRD+ Pre-transplant
NCT03624530Phase 3Unknown
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Aug 2018
- Primary completion
- Jul 2021
- Countries
- 1
01
Overview
Phase 3, open-label trial in Acute lymphoblastic leukemia, Philadelphia chromosome positive (2 arms), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Overall survival at 2 years. Status: unknown.
02
Conditions
Acute lymphoblastic leukemia, Philadelphia chromosome positive
Beyond the preview
Go deeper on NCT03624530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03624530.